Xtant Medical Reports Financial Performance and Strategic Developments for Q2 2026

Xtant Medical’s Second Quarter 2026 Financial Results

Introduction
On August 11, 2026, Xtant Medical Holdings, Inc. (NYSE American: XTNT), a prominent player in medical technology focused on surgical solutions, reported its financial outcomes for the second quarter ending June 30, 2026. As the company navigates a challenging environment marked by strategic changes, its financial and operational metrics reveal both challenges and opportunities.

Financial Highlights

For the second quarter of 2026, Xtant Medical generated total revenue of $23.0 million, a notable drop from the $35.4 million reported in the same quarter of the previous year. This decline was primarily attributed to the sale of its non-core Coflex/CoFix assets along with its international hardware business to Companion Spine in December 2025. Additionally, a shift in the reimbursement landscape contributed to the cessation of certain license revenues, which had bolstered income up to the end of 2025.

The company experienced a gross margin of 57.9%, down from 68.6% in the prior year, as the company grappled with the fallout from the cessation of high-margin license revenues and faced increased production costs, including write-offs related to obsolete inventory.

Operating expenses soared to $22.5 million, in contrast to $19.7 million the previous year, largely due to a $5 million exclusivity fee paid to Dilon Technologies concerning a new distribution agreement aimed at bolstering its product offerings and market presence. This increased investment, albeit costly in the short term, is aimed at supporting long-term strategic goals.

The company's net loss for the quarter was $9.4 million, a significant shift from the previous year's net income of $3.6 million. In terms of adjusted EBITDA, there was an evident downturn with a loss of $2.7 million, contrasting sharply with a positive adjusted EBITDA of $6.9 million a year prior.

Strategic Business Updates

Amid these financial changes, Xtant Medical has initiated several strategic maneuvers. Notably, the firm secured an exclusive distribution agreement in the U.S. with Dilon Technologies, acquiring the rights to distribute Dilon's HEMOBLAST® Bellows. This product aids in achieving high-performance hemostasis during a range of surgical procedures. The partnership also included hiring approximately twenty members from Dilon's sales team, enhancing Xtant's capability to market and sell its biologics portfolio effectively.

In addition to this collaboration, Xtant Medical introduced the Trivium™ Shaped, the latest extension of its existing Trivium line. This new product is engineered for bone grafting procedures and comes in pre-shaped formats to enhance handling and application during surgery. The launch of Trivium™ Shaped reflects Xtant's commitment to broadening its offerings and catering to diverse surgical needs, reinforcing the company's strategy of providing innovative solutions in orthobiologics.

Sean Browne, President and CEO of Xtant Medical, conveyed optimism regarding the quarter's outcomes, stating, “The second quarter showcased our ongoing commitment to enhancing our core biologics portfolio while expanding access to healthcare providers.” Browne emphasized that the strategic partnership and new product launches are encountering receptive market feedback, which could drive recovery as the company stabilizes its operations.

Looking Ahead

As of June 30, 2026, Xtant Medical reported cash and cash equivalents totaling $9.9 million and a total indebtedness of $23.0 million. Moving forward, the firm is cautiously optimistic about its financial trajectory, although it has slightly adjusted its full-year revenue guidance range down to $99 million - $103 million, reduced from an earlier prediction of $101 million - $105 million, influenced by the performance of its biologics segment and specific products.

In a bid to elaborate further on these developments, Xtant Medical will host a conference call and webcast on August 11, 2026, at 8:30 AM ET to discuss these results with investors and stakeholders.

Conclusion
The financial performance report for Q2 2026 illustrates both the current challenges faced by Xtant Medical and its strategic initiatives aimed at fostering growth and resilience in the competitive medical technology sector. As the company continues to innovate, its future will depend on how well it can navigate these strategic investments to drive long-term success.